High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage

BMC Musculoskeletal Disorders

Tomasz Grodzicki²  Ewa Kucharska¹  Sławomir Jeka³  Katarzyna Pawlak-Buś⁵  Piotr Leszczyński⁵  Jerzy Gąsowski²  Mariusz Korkosz⁴ 

[1] Vadimed Clinic, Kraków, Poland;Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Polish Spondyloarthritis Initiative, Kraków, Poland;Department of Rheumatology and Connective Tissue Diseases, 2nd University Hospital, Bydgoszcz, Poland;Division of Rheumatology, Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Polish Spondyloarthritis Initiative, Kraków, Poland;Department of Rheumatology and Rehabilitation, University of Medical Sciences, Poznań, Poland

关键词: Wnt;    Sclerostin;    New bone formation;    BASDAI;    Ankylosing spondylitis;   

Others  :  1133437
DOI  :  10.1186/1471-2474-14-99

 received in 2012-11-24, accepted in 2013-03-05,  发布年份 2013

【 摘 要 】

Background

Clinical activity of ankylosing spondylitis (AS) predicts the natural course of the disease and the response to treatment. Several molecules are involved in new bone formation resulting in structural damage in patients with AS. However, the link between the clinical and molecular phenomena has not yet been fully established. The aim of the study was to investigate the relation between markers of bone remodeling and inflammation with clinical activity and structural damage in AS.

Methods

We assessed the serum levels of sclerostin, Dickkopf-1 protein, Wingless protein-3a, bone morphogenic protein-7, matrix metalloproteinase-3, osteoprotegerin, bone alkaline phosphatase and inflammatory markers in 50 AS patients with high disease activity (BASDAI ≥ 4), 28 with low disease activity (BASDAI <4), and 23 healthy controls. Cervical and lumbar spine x-rays were performed in 46 patients to measure structural damage (mSASSS).

Results

Sclerostin level was significantly greater in high disease activity patients than in controls. Wingless protein-3a and Dikkopf-1 protein levels were significantly lower in high activity group compared to low activity group and controls. Negative correlation was found between sclerostin and Dikkopf-1 protein in high activity group (R = −0.28, P = 0.048). The median mSASSS values were not different between patient groups.

Conclusions

Higher disease activity in AS may not be per se associated with greater new bone formation.

【 授权许可】

   
2013 Korkosz et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Braun J, Sieper J: Ankylosing spondylitis. Lancet 2007, 369(9570):1379-1390.
• [2]Lories RJ, Luyten FP, de Vlam K: Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther 2009, 11(2):221. BioMed Central Full Text
• [3]Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, Asuncion F, Li X, Ominsky M, Richards W, Schett G, Zwerina J: Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010, 69(12):2152-2159.
• [4]Rosen V: BMP and BMP inhibitors in bone. Ann N Y Acad Sci 2006, 1068:19-25.
• [5]Lories R, Luyten F: Bone morphogenic proteins in destructive and remodelling arthritis. Arthritis Res Ther 2007, 9:207-214. BioMed Central Full Text
• [6]Glass DA III, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8(5):751-764.
• [7]Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 2003, 423(6937):337-342.
• [8]Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M, Stracke J, Clark I: Matrix metalloproteinases in arthritic disease. Arthritis Res 2002, 4(Suppl 3):S39-S49. BioMed Central Full Text
• [9]Weaver CM, Peacock M, Martin BR, McCabe GP, Zhao J, Smith DL, Wastney ME: Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females. J Bone Miner Res 1997, 12(10):1714-1720.
• [10]Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J: Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther 2008, 10(5):R125. BioMed Central Full Text
• [11]Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, Baraliakos X, Listing J, Rudwaleit M, Schett G, Sieper J: High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 2012, 71(4):572-574.
• [12]Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, Colak A, Yalcin H, Gunay N, Akkoc N: Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord 2012, 13(1):191. BioMed Central Full Text
• [13]Machado PF, Landewe RF, Lie E, Kvien TK, Tore K, FAU KT, Braun JF, Baker D, van der Heijde D: Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011, 70(1):47-53.
• [14]Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G: Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009, 60(11):3257-3262.
• [15]Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP: Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010, 62(1):150-158.
• [16]Macsai CE, Foster BK, Xian CJ: Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair. J Cell Physiol 2008, 215(3):578-587.
• [17]Nalesso G, Sherwood J, Bertrand J, Pap T, Ramachandran M, De Bari C, Pitzalis C, Dell’accio F: WNT-3A modulates articular chondrocyte phenotype by activating both canonical and noncanonical pathways. J Cell Biol 2011, 193(3):551-564.